Global Neuraminidase Inhibitors Drug Market Size, Status and Forecast 2020-2026

1 Report Overview

• 1.1 Study Scope
• 1.2 Market Analysis by Type
  • 1.2.1 Global Neuraminidase Inhibitors Drug Market Size Growth Rate by Type: 2020 VS 2026
  • 1.2.2 Oseltamivir
  • 1.2.3 Zanamivir
  • 1.2.4 Peramivir
  • 1.2.5 Laninamivir
• 1.3 Market by Application
  • 1.3.1 Global Neuraminidase Inhibitors Drug Market Share by Application: 2020 VS 2026
  • 1.3.2 Hospital Pharmacy
  • 1.3.3 Retail Pharmacy
  • 1.3.4 Online Pharmacy
  • 1.3.5 Others
• 1.4 Study Objectives
• 1.5 Years Considered

2 Global Growth Trends

• 2.1 Global Neuraminidase Inhibitors Drug Market Perspective (2015-2026)
• 2.2 Global Neuraminidase Inhibitors Drug Growth Trends by Regions
  • 2.2.1 Neuraminidase Inhibitors Drug Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Neuraminidase Inhibitors Drug Historic Market Share by Regions (2015-2020)
  • 2.2.3 Neuraminidase Inhibitors Drug Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Market Restraints

3 Competition Landscape by Key Players

• 3.1 Global Top Neuraminidase Inhibitors Drug Players by Market Size
  • 3.1.1 Global Top Neuraminidase Inhibitors Drug Players by Revenue (2015-2020)
  • 3.1.2 Global Neuraminidase Inhibitors Drug Revenue Market Share by Players (2015-2020)
• 3.2 Global Neuraminidase Inhibitors Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.3 Players Covered: Ranking by Neuraminidase Inhibitors Drug Revenue
• 3.4 Global Neuraminidase Inhibitors Drug Market Concentration Ratio
  • 3.4.1 Global Neuraminidase Inhibitors Drug Market Concentration Ratio (CR5 and HHI)
  • 3.4.2 Global Top 10 and Top 5 Companies by Neuraminidase Inhibitors Drug Revenue in 2019
• 3.5 Key Players Neuraminidase Inhibitors Drug Area Served
• 3.6 Key Players Neuraminidase Inhibitors Drug Product Solution and Service
• 3.7 Date of Enter into Neuraminidase Inhibitors Drug Market
• 3.8 Mergers & Acquisitions, Expansion Plans

4 Neuraminidase Inhibitors Drug Breakdown Data by Type (2015-2026)

• 4.1 Global Neuraminidase Inhibitors Drug Historic Market Size by Type (2015-2020)
• 4.2 Global Neuraminidase Inhibitors Drug Forecasted Market Size by Type (2021-2026)

5 Neuraminidase Inhibitors Drug Breakdown Data by Application (2015-2026)

• 5.1 Global Neuraminidase Inhibitors Drug Historic Market Size by Application (2015-2020)
• 5.2 Global Neuraminidase Inhibitors Drug Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Neuraminidase Inhibitors Drug Market Size (2015-2026)
• 6.2 North America Neuraminidase Inhibitors Drug Market Size by Type (2015-2020)
• 6.3 North America Neuraminidase Inhibitors Drug Market Size by Application (2015-2020)
• 6.4 North America Neuraminidase Inhibitors Drug Market Size by Country (2015-2020)
  • 6.4.1 United States
  • 6.4.2 Canada

7 Europe

• 7.1 Europe Neuraminidase Inhibitors Drug Market Size (2015-2026)
• 7.2 Europe Neuraminidase Inhibitors Drug Market Size by Type (2015-2020)
• 7.3 Europe Neuraminidase Inhibitors Drug Market Size by Application (2015-2020)
• 7.4 Europe Neuraminidase Inhibitors Drug Market Size by Country (2015-2020)
  • 7.4.1 Germany
  • 7.4.2 France
  • 7.4.3 U.K.
  • 7.4.4 Italy
  • 7.4.5 Russia
  • 7.4.6 Nordic
  • 7.4.7 Rest of Europe

8 China

• 8.1 China Neuraminidase Inhibitors Drug Market Size (2015-2026)
• 8.2 China Neuraminidase Inhibitors Drug Market Size by Type (2015-2020)
• 8.3 China Neuraminidase Inhibitors Drug Market Size by Application (2015-2020)
• 8.4 China Neuraminidase Inhibitors Drug Market Size by Region (2015-2020)
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 South Korea
  • 8.4.4 Southeast Asia
  • 8.4.5 India
  • 8.4.6 Australia
  • 8.4.7 Rest of Asia-Pacific

9 Japan

• 9.1 Japan Neuraminidase Inhibitors Drug Market Size (2015-2026)
• 9.2 Japan Neuraminidase Inhibitors Drug Market Size by Type (2015-2020)
• 9.3 Japan Neuraminidase Inhibitors Drug Market Size by Application (2015-2020)
• 9.4 Japan Neuraminidase Inhibitors Drug Market Size by Country (2015-2020)
  • 9.4.1 Mexico
  • 9.4.2 Brazil

10 Southeast Asia

• 10.1 Southeast Asia Neuraminidase Inhibitors Drug Market Size (2015-2026)
• 10.2 Southeast Asia Neuraminidase Inhibitors Drug Market Size by Type (2015-2020)
• 10.3 Southeast Asia Neuraminidase Inhibitors Drug Market Size by Application (2015-2020)
• 10.4 Southeast Asia Neuraminidase Inhibitors Drug Market Size by Country (2015-2020)
  • 10.4.1 Turkey
  • 10.4.2 Saudi Arabia
  • 10.4.3 UAE
  • 10.4.4 Rest of Middle East & Africa

11Key Players Profiles

• 11.1 Roche
  • 11.1.1 Roche Company Details
  • 11.1.2 Roche Business Overview
  • 11.1.3 Roche Neuraminidase Inhibitors Drug Introduction
  • 11.1.4 Roche Revenue in Neuraminidase Inhibitors Drug Business (2015-2020))
  • 11.1.5 Roche Recent Development
• 11.2 GSK
  • 11.2.1 GSK Company Details
  • 11.2.2 GSK Business Overview
  • 11.2.3 GSK Neuraminidase Inhibitors Drug Introduction
  • 11.2.4 GSK Revenue in Neuraminidase Inhibitors Drug Business (2015-2020)
  • 11.2.5 GSK Recent Development
• 11.3 Gilead Sciences
  • 11.3.1 Gilead Sciences Company Details
  • 11.3.2 Gilead Sciences Business Overview
  • 11.3.3 Gilead Sciences Neuraminidase Inhibitors Drug Introduction
  • 11.3.4 Gilead Sciences Revenue in Neuraminidase Inhibitors Drug Business (2015-2020)
  • 11.3.5 Gilead Sciences Recent Development
• 11.4 Daiichi Sankyo
  • 11.4.1 Daiichi Sankyo Company Details
  • 11.4.2 Daiichi Sankyo Business Overview
  • 11.4.3 Daiichi Sankyo Neuraminidase Inhibitors Drug Introduction
  • 11.4.4 Daiichi Sankyo Revenue in Neuraminidase Inhibitors Drug Business (2015-2020)
  • 11.4.5 Daiichi Sankyo Recent Development

12Analyst's Viewpoints/Conclusions

13Appendix

• 13.1 Research Methodology
  • 13.1.1 Methodology/Research Approach
  • 13.1.2 Data Source
• 13.2 Disclaimer